) The Laboratory Animal Shared Core Resource continues to provide animal services to Cancer Center members at discounted rates. In addition to services previously provided we have added a treatment and tumor assessment service. The transgenic animal production services which were previously included in this core are now provided and described in the Transgenic/Knockout core. The Laboratory Animal core began operation in 1987, now consists of the original laboratory animal components plus the new animal model tumor testing and intervention service. The core presently serves the research animal needs of 88 Cancer Center investigators including 74 who utilize full core services in the Center for Laboratory Animal Care on the UCHSC campus. The overall objective of the core is to facilitate cancer research and provide Cancer Center investigators with high quality, centralized and specialized services for animal experimentation at reduced and cost effective prices. This shared resource provides routine and specialized maintenance of conventional and barrier- sustained, specific-pathogen-free (SPF) rodents, conventional laboratory animals and transgenic/knockout rodents as well as severe combined immunodeficient (SCID) and athymic, nude mice and rats for allo- and xenografts of tumors and tumor testing, growth and intervention studies. New therapies may be delivered by intravenous, intraperitoneal, transtracheal, intratumoral, intragenic or other routes. Samples for pharmacokinetic analysis are collected for evaluation in the Pharmacology core. The Laboratory Animal core also provides monoclonal and polyclonal antibody production services, gross and histopathology, medical photography and photo microscopy , tumor harvests and transfers, animal model development, preparations and manipulations, training in animal research techniques and laboratory animal veterinary services. The primary goal is to provide state of the art, high quality animal maintenance and research services to Cancer Center investigators that are affordable and accessible.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-15
Application #
6589971
Study Section
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456

Showing the most recent 10 out of 1634 publications